 Connection
Elaine Lam to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Elaine Lam has written about Dose-Response Relationship, Drug.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.127 |
|
|
|
-
Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Feb; 69(2):523-31.
Score: 0.066
-
Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol. 2022 07; 90(1):7-17.
Score: 0.035
-
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018 03 20; 36(9):867-874.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|